Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × birinapant × Clear all
NCT02756130 2025-05-13

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Jonsson Comprehensive Cancer Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡